Molecular Medicine

, Volume 10, Issue 7–12, pp 117–123 | Cite as

Genomic Imprinting of IGF2 Is Maintained in Infantile Hemangioma despite its High Level of Expression

  • Ying Yu
  • Jill Wylie-Sears
  • Elisa Boscolo
  • John B Mulliken
  • Joyce Bischoff


Hemangioma, the most common tumor of infancy, is characterized by rapid growth and slow regression. Increased mRNA expression of insulin-like growth factor 2 (IGF2) has been detected in the proliferating phase by cDNA microarray analysis, but the underlying mechanism causing the increase remains unknown. Here, using quantitative real-time polymerase chain reaction (PCR) and immunohistochemistry, we show that IGF2 is highly expressed in both proliferating and involuting phase hemangioma, but is not detectable in other vascular lesions such as pyogenic granuloma, venous malformation, lymphatic malformation, or in normal infant skin. Loss of imprinting of the Igf2 gene has been associated with IGF2 overexpression in a variety of childhood tumors. To determine if loss of imprinting and consequent bi-allelic expression might contribute to the increased expression of IGF2, we examined the genomic imprinting status of Igf2 in 48 individual hemangiomas. We determined allele-specific Igf2 expression using reverse transcriptase-PCR combined with analysis of an Apa I-sensitive restriction fragment length polymorphism. Similar to heterozygous normal skin controls, all 15 informative hemangiomas showed uniform mono-allelic expression of Igf2. Therefore, loss of imprinting is not involved in the increased expression of IGF2 in infantile hemangioma.



This study is supported by grants from the NIH (P01 AR048564) and the John Butler Mulliken Foundation. We thank Drs. Zia Khan and Carmen Barnes, both members of the Vascular Biology Program, Children’s Hospital Boston, for advice on real-time PCR quantitative analysis and human placental RNA samples, respectively.


  1. 1.
    Holmdahl K. (1955) Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 44:370–9.CrossRefGoogle Scholar
  2. 2.
    Mulliken JB. (1993) Cutaneous vascular anomalies. Semin. Vasc. Surg. 6:204–18.PubMedGoogle Scholar
  3. 3.
    Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 93:2357–64.CrossRefGoogle Scholar
  4. 4.
    Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J. (2004) Endothelial progenitor cells in infantile hemangioma. Blood 103:1373–5.CrossRefGoogle Scholar
  5. 5.
    Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. (2001) Clonality and altered behavior of endothelial cells from hemangiomas. J. Clin. Invest. 107:745–52.CrossRefGoogle Scholar
  6. 6.
    Walter JW et al. (2002) Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 33:295–303.CrossRefGoogle Scholar
  7. 7.
    Ezekowitz RA, Mulliken JB, Folkman J. (1992) Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326:1456–63.CrossRefGoogle Scholar
  8. 8.
    Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC. (2004) Vincristine as a treatment for a large haemangioma threatening vital functions. Br. J. Plast. Surg. 57:168–171.CrossRefGoogle Scholar
  9. 9.
    Barlow CF et al. (1998) Spastic diplegia as a complication of interferon Alpha-2a treatment of hemangiomas of infancy. J. Pediatr. 132:527–30.CrossRefGoogle Scholar
  10. 10.
    Worle H, Maass E, Kohler B, Treuner J. (1999) Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. Eur. J. Pediatr. 158:344.CrossRefGoogle Scholar
  11. 11.
    Boon LM, MacDonald DM, Mulliken JB. (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast. Reconstr. Surg. 104: 1616–23.CrossRefGoogle Scholar
  12. 12.
    Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. (1993) Parental genomic imprinting of the human IGF2 gene. Nat. Genet. 4:98–101.CrossRefGoogle Scholar
  13. 13.
    Arney KL. (2003) H19 and Igf2—enhancing the confusion? Trends Genet. 19: 17–23.CrossRefGoogle Scholar
  14. 14.
    Rainier S et al. (1993) Relaxation of imprinted genes in human cancer. Nature 362:747–9.CrossRefGoogle Scholar
  15. 15.
    Cui H et al. (2001) Loss of imprinting of insulin-like growth factor-II in Wilms’ tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 61:4947–50.PubMedGoogle Scholar
  16. 16.
    Yun K. (1998) Genomic imprinting and carcinogenesis. Histol. Histopathol. 13: 425–35.PubMedGoogle Scholar
  17. 17.
    Schneider DT et al. (2001) Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer Res. 61:7268–76.PubMedGoogle Scholar
  18. 18.
    Weksberg R, Smith AC, Squire J, Sadowski P. (2003) Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum. Mol. Genet. 12 Spec No 1:R61–8.CrossRefGoogle Scholar
  19. 19.
    Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. (2000) Loss of IGF-II imprinting in endometrial tumors: overexpression in carcinosarcoma. CancerLett. 153:67–73.Google Scholar
  20. 20.
    Muller S, Zirkel D, Westphal M, Zumkeller W. (2000) Genomic imprinting of IGF2 and H19 in human meningiomas. Eur. J. Cancer 36:651–5.CrossRefGoogle Scholar
  21. 21.
    Ogawa O et al. (1993) Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumor. Nature 362:749–51.CrossRefGoogle Scholar
  22. 22.
    Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. (2002) Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc. Natl. Acad. Sci. U.S.A. 99: 7455–60.CrossRefGoogle Scholar
  23. 23.
    Tadokoro K, Fujii H, Inoue T, Yamada M. (1991) Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res. 19:6967.CrossRefGoogle Scholar
  24. 24.
    Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. (2001) Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am. J. Pathol. 159: 2271–80.CrossRefGoogle Scholar
  25. 25.
    Ginzinger DG. (2002) Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. Hematol. 30:503–12.CrossRefGoogle Scholar
  26. 26.
    Boon LM, Enjolras O, Mulliken JB. (1996) Congenital hemangioma: evidence of accelerated involution. J. Pediatr. 128:329–35.CrossRefGoogle Scholar
  27. 27.
    Enjolras O, Mulliken JB. (1998) Vascular tumors and vascular malformations, new issues. In: Adv. Dermatol. Paller AS (ed.) Mosby-Year Book, Inc., St. Louis, Mo, pp. 375–422.Google Scholar
  28. 28.
    North PE, Waner M, Mizeracki A, Mihm Jr. MC. (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum. Pathol. 31:11–22.CrossRefGoogle Scholar
  29. 29.
    North PE et al. (2001) Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma. Arch. Dermatol. 137: 1607–20.CrossRefGoogle Scholar
  30. 30.
    Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. (1998) Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4:1276–80.CrossRefGoogle Scholar
  31. 31.
    Jones JI, Clemmons DR. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:3–34.PubMedGoogle Scholar
  32. 32.
    Le Roith D. (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med. 336:633–40.CrossRefGoogle Scholar
  33. 33.
    Li Q, Yu Y, Bischoff J, Mulliken JB, Olsen BR. (2003) Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J. Pathol. 201:296–302.CrossRefGoogle Scholar
  34. 34.
    Razon MJ, Kraling BM, Mulliken JB, Bischoff J. (1998) Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 5: 189–95.CrossRefGoogle Scholar
  35. 35.
    Kim KW et al. (1998) Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 58:348–51.PubMedGoogle Scholar
  36. 36.
    Lee OH et al. (2000) Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. Br. J. Cancer 82:385–91.CrossRefGoogle Scholar
  37. 37.
    Feldser D et al. (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 59:3915–8.PubMedGoogle Scholar
  38. 38.
    Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276:9519–25.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2004

Authors and Affiliations

  • Ying Yu
    • 1
    • 3
  • Jill Wylie-Sears
    • 1
  • Elisa Boscolo
    • 1
  • John B Mulliken
    • 2
    • 3
  • Joyce Bischoff
    • 1
    • 3
  1. 1.Vascular Biology Program and Department of SurgeryChildren’s Hospital BostonBostonUSA
  2. 2.Division of Plastic SurgeryChildren’s Hospital BostonBostonUSA
  3. 3.Department of SurgeyHarvard Medical SchoolBostonUSA

Personalised recommendations